Product logins

Find logins to all Clarivate products below.


  • The number of total prevalent cases of MCI across the countries under study will increase by 39%, from 2.8 million in to 3.9 million in 10 years.
  • Among the countries considered in this analysis, the total prevalence of MCI is highest in Canada, at 179 per 1,000 aged 65 or over in 2020.
  • 58% of all total prevalent cases of MCI in the countries under study are female. 

Related Market Assessment Reports

Report
Multiple Sclerosis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab…
Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early…
Report
Amyotrophic Lateral Sclerosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Amyotrophic lateral sclerosis (ALS) is a disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of…
Report
Inflammatory Myositis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of inflammatory myositis (IM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Report
Genitourinary Syndrome of Menopause – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of GSM comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy,…